I think this clinical practice guideline (CPG) reflects an American
prescribing bias.
There are several problems with the methods used:
1. The levels of evidence are not the ones widely used today, A, B, C
and
D, as defined in http://www.cebm.net/levels_of_evidence.asp
2. It references an outdated Cochrane review, which now is updated
(1),
and more restrictive to antibiotics in areas where the mastoiditis rates
are low.
3. It does not cite Clinical Evidence (www.clinicalevidence.com),
which
also is more restrictive to antibiotics.
4. I do not understand how the proposed algorithm in Fig. 1 could be
derived from data in table 5, which shows non-significant differences in
8 of 11 outcomes when comparing initial antibacterial therapy with
initial observation. Further, there is a 16% risk of side-effects.
Implementing this guideline in my country would raise the
prescription
rate. As I see it, this CPG could as well have suggested initial
observation
with analgesia for all.
Reference
1. Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics for
acute
otitis media in children (Cochrane Review). In: The Cochrane Library,
Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.